Allogene Therapeutics (ALLO) vs Autolus Therapeutics (AUTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 21.5% versus a gain of 5.9%. Over five years, AUTL leads with a -70.5% price change compared with -91.3% for ALLO. Allogene Therapeutics is the larger company by market cap ($494.1 million vs $481.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | AUTL |
|---|---|---|
| Share price | $1.43 | $1.81 |
| Market cap | $494.05M | $481.75M |
| 1-day change | -2.05% | +1.12% |
| YTD return | +4.38% | -9.05% |
| 1-year return | +5.93% | +21.48% |
| 5-year return | -91.32% | -70.52% |
| EPS (TTM) | $-0.66 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $2.58 |
| 52-week low | $1.04 | $1.18 |
| Distance from 52-week high | -67.94% | -29.84% |
| Average volume | 5.78M | 2.10M |
| Shares outstanding | 345.49M | 266.16M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed ALLO by 15.6 percentage points over the past year.
ALLO vs AUTL FAQ
Which is bigger, Allogene Therapeutics or Autolus Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $494.05M compared with $481.75M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, ALLO or AUTL?
AUTL returned +21.48% over the past 12 months, compared with +5.93% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Autolus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.